Mark Erlander's guest appearances

Mark Erlander

Empowered Patient Podcast

Random Musings From The Clinical Trials Guru

trialsitenews's podcast

Craig Lipset

Hartmut Ehrlich

Amolyt Pharma

Jordan Dubow

Sonny Hsiao

Raphael Stricker

Thierry Abribat Amolyt Pharma

James Sapirstein

Mel Kaspin Blume

Tzvia Bader

Michele Dilizia Recce

Sheri Prentiss

Dan Gold

Jordan Dubow Avadel

Elizabeth Jeffords

OwlTail

Mark Erlander, Chief Executive Officer at #CardiffOncology, Inc. talks #KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal #Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more here

Mark Erlander, Chief Executive Officer at #CardiffOncology, Inc. talks #KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal #Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more <a href="https://cardiffoncology.com/mcrc/" rel="nofollow" target="_blank">here</a>

Mark Erlander of Cardiff Oncology, Inc. Discusses KRAS Mutations in Cancer | Podcast S2 E39

Dr. Mark Erlander, CEO, Cardiff Oncology identifies the unmet needs of those suffering from metastatic colorectal cancer who have the oncogene KRAS mutation that hyper-drives the tumor growth.  Mark talks about the company's investigational drug, onvansertib that is being evaluated in metastatic colorectal cancer (mCRC), acute myeloid leukemia (AML), and metastatic castrate-resistant prostate cancer (mCRPC).  Onvansertib is a first-in-class, third-generation, oral and highly-selective inhibitor of PLK1, an enzyme that is over-expressed in most types of cancers. Onvansertib works synergistically in combination with approved chemotherapies and targeted therapeutics. @CardiffOncology #onvansertib #cancer #oncology #drugdevelopment #colorectalcancer #KRAS Cardiffoncology.com Download the transcript here

Dr. Mark Erlander, CEO, Cardiff Oncology identifies the unmet needs of those suffering from metastatic colorectal cancer who have the oncogene KRAS mutation that hyper-drives the tumor growth.  Mark talks about the company's investigational drug, onvansertib that is being evaluated in metastatic colorectal cancer (mCRC), acute myeloid leukemia (AML), and metastatic castrate-resistant prostate cancer (mCRPC).  Onvansertib is a first-in-class, third-generation, oral and highly-selective inhibitor of PLK1, an enzyme that is over-expressed in most types of cancers. Onvansertib works synergistically in combination with approved chemotherapies and targeted therapeutics.<a href="http://cardiffoncology.com" rel="noopener nofollow" target="_blank"></a> @CardiffOncology #onvansertib #cancer #oncology #drugdevelopment #colorectalcancer #KRAS <a href="http://cardiffoncology.com" rel="noopener nofollow" target="_blank">Cardiffoncology.com</a> <a href="http://empoweredpatientradio.com/treating-metastatic-colorectal-cancer-with-kras-biomarker-with-dr-mark-erlander-cardiff-oncology-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Treating Metastatic Colorectal Cancer with KRAS Biomarker With Dr. Mark Erlander Cardiff Oncology

Mark’s LinkedIn: https://www.linkedin.com/in/mark-erlander-ph-d-33669269/Text me: (949) 415-6256  My podcast is Random Musings From The Clinical Trials Guru  GET THE BOOK! https://www.amazon.com/dp/1090349521/... Text "guru" to 31996 to join VIP list!  My blog: http://www.TheClinicalTrialsGuru.com My business Patreon Page: http://www.patreon.com/dansfera Site Owner Academy: http://www.theclinicaltrialsguru.com/...  My CRO: http://www.DSCScro.com My CRA Academy: http://www.TheCRAacademy.com My CRC Academy: http://www.thecrcacademy.com

Mark’s LinkedIn: <a href="https://www.linkedin.com/in/mark-erlander-ph-d-33669269/" rel="nofollow" target="_blank">https://www.linkedin.com/in/mark-erlander-ph-d-33669269/</a>Text me: (949) 415-6256 My podcast is Random Musings From The Clinical Trials Guru GET THE BOOK! <a href="https://www.amazon.com/dp/1090349521/" rel="nofollow" target="_blank">https://www.amazon.com/dp/1090349521/</a>... Text "guru" to 31996 to join VIP list! My blog: <a href="http://www.TheClinicalTrialsGuru.com" rel="nofollow" target="_blank">http://www.TheClinicalTrialsGuru.com</a> My business Patreon Page: <a href="http://www.patreon.com/dansfera" rel="nofollow" target="_blank">http://www.patreon.com/dansfera</a> Site Owner Academy: <a href="http://www.theclinicaltrialsguru.com/" rel="nofollow" target="_blank">http://www.theclinicaltrialsguru.com/</a>... My CRO: <a href="http://www.DSCScro.com" rel="nofollow" target="_blank">http://www.DSCScro.com</a> My CRA Academy: <a href="http://www.TheCRAacademy.com" rel="nofollow" target="_blank">http://www.TheCRAacademy.com</a> My CRC Academy: <a href="http://www.thecrcacademy.com" rel="nofollow" target="_blank">http://www.thecrcacademy.com</a>

Dr. Mark Erlander From Trovagene Discusses Colorectal Cancer Initiatives Ep.358